Patient enrolment concludes in Glaukos’ Preserflo MicroShunt trial

Glaukos has concluded patient enrolment in its US 510 (k) pivotal trial assessing the Preserflo MicroShunt drainage device in adults with primary open-angle glaucoma. The study targets patients whose ...
MassDevice

Glaukos completes enrollment in Preserflo MicroShunt study

Glaukos (NYSE:GKOS) announced today that it completed enrollment in a pivotal study evaluating its Preserflo MicroShunt ...

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today ...
Ophthalmology Times

Glaukos completes enrollment in pivotal trial of PRESERFLO MicroShunt for treatment-resistant glaucoma

Glaukos finishes US pivotal enrollment for PRESERFLO MicroShunt, targeting advanced glaucoma after failed surgeries, with ...
IEEE

Glaucoma Grading Using Multimodal Imaging and Multilevel CNN

Abstract: Glaucoma is considered the leading cause of blindness. Because there is no cure for the disease, treatment must begin promptly to prevent disease progression, which leads to severe visual ...